Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease

Sep 13, 2019 18:43 JST

Source: Eisai

Discontinuation of studies based on Data Safety Monitoring Board recommendation

TOKYO, Sep 13, 2019 - (JCN Newswire) - Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD). The decision is based on the results of a safety review conducted by the Data Safety Monitoring Board (DSMB), which recommended to discontinue these trials due to an unfavorable risk-benefit ratio. Detailed data of these studies will be presented at future medical meetings.

Investigators are being informed of the decision and they will be contacting their study participants to discontinue the investigational treatment.

Dr. Lynn Kramer, Chief Clinical Officer, Neurology Business Group, Eisai Co., Ltd., said: "We would like to thank the patients and the families, as well as medical professionals, that participated in the MISSION AD studies. Without their contributions we would not be able to advance Alzheimer's disease research. We are very disappointed with the news, and intend to learn from these data and continue engaging with patients and investigators, to pursue the discovery of new medicines for Alzheimer's disease."

The Phase III clinical trial program for elenbecestat (MISSION AD) consisted of two global Phase III clinical studies with identical protocols, MISSION AD1 (Study 301) and MISSION AD2 (Study 302). Both studies were multicenter, placebo-controlled, double-blind, parallel-group Phase III clinical studies designed to assess the efficacy and safety of elenbecestat for treatment in a total of about 2,100 patients with mild cognitive impairment (MCI) or mild AD (collectively known as early AD) with confirmed amyloid pathology in the brain. Patients were randomized to receive either 50 mg of elenbecestat or placebo daily during the treatment period of 24 months, and the primary endpoint was the Clinical Dementia Rating Sum of Boxes (CDR-SB).

As part of this decision, the long-term extension of the Phase II clinical trial of elenbecestat (Study 202) will also be discontinued. This determination does not impact the program of the anti-amyloid beta (Abeta) protofibril monoclonal antibody BAN2401, and the Phase III Clarity AD trial of BAN2401 will continue.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026

May 21 2026 23:23 JST

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

April 21 2026 19:52 JST

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

March 27 2026 19:14 JST

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

March 27 2026 17:19 JST

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026

March 23 2026 10:19 JST

Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)

March 19 2026 09:54 JST

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

March 17 2026 18:49 JST

Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration

March 12 2026 16:21 JST

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

March 11 2026 11:07 JST

WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

March 02 2026 08:49 JST

More Press release >>

Latest Press Release

Fujitsu provides core business system for real-time information management of all Japan Maritime Self-Defense Force supplies
May 26, 2026 19:20 JST

Fujitsu's groundbreaking computing technology for accelerating scientific computing wins the Prime Minister's Prize in Japan
May 26, 2026 13:50 JST

NTT, Kubota and NTT DOCOMO Demonstrate Communication Technologies Enabling Remote Operation of Robotic Agricultural Machinery in Mountainous Areas
May 26, 2026 13:30 JST

Successful Demonstration of Stable, High-Capacity mmWave Communications for Multiple High-Speed Vehicles for the 6G Era
May 25, 2026 14:58 JST

Fujitsu develops self-evolving multi-AI agent technology that learns and adapts to business operations
May 25, 2026 14:13 JST

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 00:23 JST

Honda to Begin Sales of Super-ONE Compact EV
May 22, 2026 00:16 JST

Fujitsu supports the Panasonic Group in accelerating its sustainability management through the implementation of a CFP calculation solution
May 21, 2026 13:57 JST

Sharp Launches Poketomo Conversational AI Character in Taiwan
May 21, 2026 13:55 JST

Hitachi Energy's HMAX Energy service solutions strengthen long-term reliability for Akaysha Energy's Ulinda Park BESS
May 21, 2026 13:40 JST

Heads of State/Government, Ministers, and Senior Officials from 30 Countries to Convene in Tokyo for the Island States Ocean Summit
May 20, 2026 17:00 JST

Trusco Nakayama and Fujitsu accelerate personnel transfer decision-making process with data and AI
May 20, 2026 13:50 JST

Hitachi announces strategic partnership with Anthropic to strengthen "Lumada 3.0" through frontier AI
May 19, 2026 23:09 JST

SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
May 19, 2026 13:37 JST

Ashikaga Bank launches Fujitsu's service supporting digitalization of Inheritance Procedure
May 18, 2026 18:13 JST

Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST

MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST

MHI Thermal Systems Receives A' Design Awards
-- Recognition at Italy's International Design Competition for the Hydrolution EZY Series of Air-to-Water Heat Pumps and the ZT Series of Residential-Use Air-Conditioners --
May 18, 2026 16:26 JST

Tallgrass and Mitsubishi Power Americas Announce Turbine Allocation for Cheyenne Power Hub
May 18, 2026 15:15 JST

JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST

More Latest Release >>